Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Brentuximab vedotin (BV) plus chemotherapy with the drugs cyclophosphamide, doxorubicin, and prednisone (CHP) is a standard treatment for T-cell lymphomas that make the CD30 protein. Researchers want to see if BV with an enhanced chemotherapy regimen that includes etoposide works better in people with T-cell lymphomas.
Researchers want to see if it is practical to give immunotherapy before kidney cancer surgery. The people in this study have no evidence of cancer spread in other parts of their body. Researchers also want to see if this treatment causes any delays in surgery. Immunotherapy is treatment that boosts the body's natural defenses to fight cancer.
Mirdametinib blocks proteins called MEK1 and MEK2, which play an important role in cancer cell growth and survival. By blocking MEK1 and MEK2, mirdametinib may slow or stop the growth of your cancer.
In addition, their cancers have a fusion (change) in the ALK gene. The fusion gene makes a protein that promotes cancer growth and survival. This type of cancer is called ALK-positive NSCLC.
Researchers are comparing different sequences of therapy for people with newly diagnosed multiple myeloma. All participants will get cilta-cel CAR T-cell therapy, a form of immunotherapy made from your own white blood cells.
Researchers want to find the best dose of DCC-3116 to give with ripretinib for people with gastrointestinal stromal tumor (GIST). The people in this study have GIST that has spread, even with treatment.
The purpose of this study is to find the highest dose of the investigational drug glofitamab that can be given safely alone or with obinutuzumab in patients with non-Hodgkin lymphoma that came back or continued to grow despite treatment. Glofitamab is a "bispecific antibody" that binds to two different proteins: one found on the surface of cancer cells and one found on the surface of immune cells. Researchers think that glofitamab may strengthen the immune system's ability to fight cancer cells by activating a patient's own cells to destroy the tumor. Both drugs are given intravenously (by vein).
Peritoneal mesothelioma is a cancer of the inner lining of the abdomen (belly). The people in this study will be having surgery to take out as much of the cancer as possible. They will also receive heated chemotherapy given directly into the abdomen to kill any remaining cancer cells.
Researchers want to find the best dose of lorlatinib to give with ramucirumab in people with lung cancer. They are also seeing how well this drug combination works. The people in this study have non-small cell lung cancer (NSCLC) that has metastasized (spread). In addition, their cancers have a fusion involving the ALK gene. A fusion gene is made when parts of two different genes in your body join together.
In this study, researchers want to see how well a personalized vaccine works for people with pancreatic cancer. The people in this study have pancreatic cancer that can be taken out with surgery. The vaccine is called autogene cevumeran. It is an "mRNA vaccine," made in a way similar to the vaccines used to prevent COVID. It will be given in combination with a drug called atezolizumab and a chemotherapy treatment called mFOLFIRINOX.
